focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4XD.L Share News (C4XD)

  • There is currently no data for C4XD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

Wed, 03rd Jan 2024 10:12

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

C4X Discovery Holdings PLC, up 34% at 11.75 pence, 12-month range 7.63p-22.00p. The drug discovery company focussed on immuno-inflammatory diseases receives a USD11.0 million milestone payment from FTSE 100-listed pharmaceutical firm AstraZeneca PLC, following trials of the C4X respiratory disease therapy treatment. The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November. In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.

----------

Getech Group PLC, up 29% at 6.75p, 12-month range 4.10p-17.43p. The geo-energy and green hydrogen company says it has won eight new contracts, worth GBP1.8 million in total. The deals comprise of subscriptions to Getech's Globe platform, geoscience data and the purchase of expert consulting services. It expects to recognise GBP600,000 of revenue from these contracts in its 2023 earnings. Acting Chief Executive Officer Richard Bennett says: "Entering 2024 with our substantially reduced costbase, increased order book and growing [annual recurring revenue] means the business is undoubtedly better placed following a year of transition in 2023. We have also invested in expanding our exploration capabilities, targeting resources associated with the energy transition. The recent Cop28 demonstrated again the world's commitment to phasing down fossil fuels and in 2024 we expect to benefit from this by helping our customers locate the subsurface future facing resources such as critical minerals and geothermal projects that are so vital to the energy transition."

----------

AIM - LOSERS

----------

Mkango Resources Ltd, down 7.3% at 9.50p, 12-month range 8.00p-17.41p. The mineral exploration and development company says that its subsidiary Maginito Ltd will partner with CoTec Holdings Corp to roll out scrap magnetic recycling technology in the US. The partnership will focus on promoting HyProMag Ltd's technology. HyProMag is a rare earth magnet recycling company in which Maginito holds a 100% stake, and is commercialising its technology in the UK, Germany and US. The 50-50 joint venture will initially involve a bankable feasibility study using three hydrogen processing of magnet scrap vessels and a magnet manufacturing hub. Following this, Mkango and CoTec will decide whether to proceed with the construction of the US project. Revenue from the project is targeted for either 2025 or 2026. The pair recently issued a request for proposal process from "leading engineering, procurement and construction management providers", and has ordered three HPMS reactors to expedite the US project.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 May 2020 17:57

C4X Discovery Raises GBP1.6 Million Via Share Placing

C4X Discovery Raises GBP1.6 Million Via Share Placing

Read more
24 Jan 2020 15:59

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
7 Jan 2020 10:40

C4X Discovery Annual Loss Widens, Confident In Strategy

C4X Discovery Annual Loss Widens, Confident In Strategy

Read more
7 Jan 2020 09:59

C4X losses widen as its revenue drops to nil

(Sharecast News) - Drug discovery company C4X Discovery Holdings announced a fall in revenue to nil in its full-year results on Tuesday, from £7.06m in 2018, which the board said as driven entirely by the Indivior licensing agreement in that year.

Read more
31 Dec 2019 10:47

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
24 Oct 2019 17:06

UPDATE: C4X Discovery Raises GBP7 Million In Discounted Placing

UPDATE: C4X Discovery Raises GBP7 Million In Discounted Placing

Read more
24 Oct 2019 11:09

C4X Discovery Raises Over GBP5 Million In Discounted Placing

C4X Discovery Raises Over GBP5 Million In Discounted Placing

Read more
24 Oct 2019 10:31

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

Read more
1 Oct 2019 10:15

C4X makes solid progress across portfolio of programmes

(Sharecast News) - Drug discovery company C4X Discovery Holdings announced progress across a number of key programmes in line with its strategy on Tuesday, reporting that it was continuing to progress its strategy to deliver programmes for out-licensing its NRF-2 activator, IL-17 inhibitor and LifeArc collaboration.

Read more
27 Sep 2019 15:39

C4X upbeat as its molecule progresses with Indivior

(Sharecast News) - Drug discovery company C4X Discovery Holdings noted an announcement on Friday that the National Institutes of Health (NIH) in the United States has granted Indivior's application titled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder'.

Read more
2 Sep 2019 12:02

Former Glaxo Vice President To Lead C4X Discovery Advisory Network

(Alliance News) - C4X Discovery Holdings PLC on Monday said it is forming a drug discovery advisory network chaired by "renowned industry veteran" Robin Carr.Shares in C4X were up

Read more
30 Apr 2019 12:59

C4X Discovery Interim Loss Widens, Focuses On Inking Deals

LONDON (Alliance News) - C4X Discovery Holdings PLC said on Tuesday it had a "strong" first half, though its loss widened on higher research and development costs.The drug firm to

Read more
23 Apr 2019 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 24 April PetropavolskFull Year ResultsBoohoo GroupFull Year HealthFull

Read more
6 Dec 2018 16:04

E-Therapeutics and C4X upbeat on Parkinson's collaboration

(Sharecast News) - Network-driven drug discovery company e-Therapeutics and C4X Discovery Holdings updated the market on their collaboration on Thursday, to identify novel intervention strategies for the potential treatment of Parkinson's Disease (PD).

Read more
6 Dec 2018 09:23

e-Therapeutics And C4X Identify New Pathways For Parkinson's Treatment

LONDON (Alliance News) - C4X Discovery Holdings PLC and e-Therapeutics PLC on Thursday said that, through their collaboration, they discovered additional novel biological pathways for the of that

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.